Kura Oncology Stock News

Kura Oncology Inc (NASDAQ:KURA) – Investment analysts at Svb Leerink decreased their FY2020 EPS estimates for Kura Oncology in a research note issued to investors on Wednesday, February 26th. Svb Le

Kura Oncology Inc (NASDAQ:KURA) – Analysts at Wedbush decreased their Q1 2020 earnings per share (EPS) estimates for Kura Oncology in a research report issued on Wednesday, February 26th. Wedbush an

Fmr LLC lifted its holdings in shares of Kura Oncology Inc (NASDAQ:KURA) by 1.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm o

Kura Oncology Inc (NASDAQ:KURA) – Research analysts at Piper Sandler cut their FY2022 EPS estimates for shares of Kura Oncology in a note issued to investors on Tuesday, February 25th. Piper Sandler

Kura Oncology Inc (NASDAQ:KURA) – Equities researchers at Piper Sandler issued their FY2024 EPS estimates for Kura Oncology in a report issued on Tuesday, February 25th. Piper Sandler analyst T. Van

Kura Oncology Inc (NASDAQ:KURA) – Equities research analysts at Oppenheimer issued their FY2024 earnings per share estimates for Kura Oncology in a research note issued on Tuesday, February 25th. Op

Kura Oncology (NASDAQ:KURA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday, Zacks.com reports

Kura Oncology Inc (NASDAQ:KURA) – Stock analysts at Svb Leerink issued their Q1 2020 EPS estimates for Kura Oncology in a research note issued on Wednesday, February 26th. Svb Leerink analyst J. Cha

Kura Oncology Inc (NASDAQ:KURA)’s share price reached a new 52-week low on Thursday after Piper Sandler lowered their price target on the stock from to . The stock traded as low as $11.41 and last t

After Cowen & Co. and Oppenheimer gave Kura Oncology (NASDAQ: KURA) a Buy rating last month, the company received another Buy, this time from H.C.

After Cowen & Co. and Oppenheimer gave Kura Oncology (NASDAQ: KURA ) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Joseph Pantginis reiterated a Bu

KURA earnings call for the period ending December 31, 2019.

Q4 2019 Kura Oncology Inc Earnings Call

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Kura Oncology (KURA) yesterday. The company's shares closed last Monday at $12.46,

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Kura Oncology (KURA – Research Report) yesterday. The company’s